Literature DB >> 29081384

Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience.

Valerio Gallotta1, Carmine Conte2, Maria Teresa Giudice2, Camilla Nero2, Giuseppe Vizzielli2, Salvatore Gueli Alletti2, Stefano Cianci2, Claudio Lodoli3, Andrea Di Giorgio3, Agostino Maria De Rose4, Anna Fagotti2, Giovanni Scambia2, Gabriella Ferrandina5.   

Abstract

STUDY
OBJECTIVE: To analyze the feasibility and safety of laparoscopic secondary cytoreductive surgery in a retrospective series of patients with platinum-sensitive recurrent ovarian cancer.
DESIGN: Retrospective cohort study (Canadian Task Force classification II-2).
SETTING: Catholic University of the Sacred Heart, Rome, Italy. PATIENTS: Between October 2010 and October 2016, 58 patients with recurrent ovarian cancer were selected for a retrospective analysis of data.
INTERVENTIONS: All patients underwent a laparoscopic secondary cytoreduction with single or multiple procedures.
RESULTS: The most frequent pattern of recurrence was peritoneal (48.3%); 6 patients (10.3%) experienced parenchymal disease (spleen, n = 5; liver, n = 1), and 24 patients (41.4%) had lymph node recurrence. Complete debulking was achieved in all patients. The median operative time was 204 minutes (range, 55-448 minutes), median estimated blood loss was 70 mL (range, 20-300 mL), and the median length of hospital stay was 4 days (range, 1-21 days). Four patients (6.8%) experienced intraoperative complications. Early postoperative complications were documented in 6 patients (10.3%), but only 1 G3 complication was noted. The median duration of follow-up since secondary cytoreduction was 24 months (range, 9-71 months). Twenty-one patients (36.2%) experienced a second disease relapse. The median progression-free survival (PFS) was 28 months, and the 2-year PFS was 58.7%. Five patients died (8.6%); the 2-year overall survival was 90.7%.
CONCLUSIONS: For selected patients, laparoscopy is a feasible and safe approach to optimal cytoreduction for patients with recurrent ovarian cancer.
Copyright © 2017 American Association of Gynecologic Laparoscopists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Laparoscopy; Recurrent ovarian cancer; Secondary cytoreduction

Mesh:

Year:  2017        PMID: 29081384     DOI: 10.1016/j.jmig.2017.10.024

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  17 in total

1.  Robotic Single-Port Platform in General, Urologic, and Gynecologic Surgeries: A Systematic Review of the Literature and Meta-analysis.

Authors:  S Cianci; A Rosati; V Rumolo; S Gueli Alletti; V Gallotta; L C Turco; G Corrado; G Vizzielli; A Fagotti; F Fanfani; G Scambia; S Uccella
Journal:  World J Surg       Date:  2019-10       Impact factor: 3.352

2.  A novel HIPEC technique using hybrid CO2 recirculation system: intra-abdominal diffusion test in a porcine model.

Authors:  Stefano Cianci; Giuseppe Vizzielli; Anna Fagotti; Fabio Pacelli; Andrea Di Giorgio; Alessandro Tropea; Antonio Biondi; Giovanni Scambia
Journal:  Updates Surg       Date:  2018-06-25

Review 3.  Laparotomy vs. minimally invasive surgery for ovarian cancer recurrence: a systematic review.

Authors:  Stefano Uccella; Massimo P Franchi; Stefano Cianci; Pier Carlo Zorzato; Francesca Bertoli; Salvatore Gueli Alletti; Fabio Ghezzi; Giovanni Scambia
Journal:  Gland Surg       Date:  2020-08

4.  Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis.

Authors:  L Rodríguez-Ortiz; A Arjona-Sánchez; M Ibañez-Rubio; J Sánchez-Hidalgo; A Casado-Adam; S Rufián-Peña; J Briceño-Delgado
Journal:  Surg Endosc       Date:  2020-04-23       Impact factor: 4.584

Review 5.  The robotic single-port platform for gynecologic surgery: a systematic review of the literature and meta-analysis.

Authors:  Vito Andrea Capozzi; Giulia Armano; Andrea Rosati; Alessandro Tropea; Antonio Biondi
Journal:  Updates Surg       Date:  2020-05-29

6.  Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience.

Authors:  Giuseppe Scaletta; Lorena Quagliozzi; Stefano Cianci; Virginia Vargiu; Maria Cristina Mele; Giovanni Scambia; Anna Fagotti
Journal:  Updates Surg       Date:  2019-04-20

Review 7.  Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option.

Authors:  Vito Andrea Capozzi; Andrea Rosati; Luigi Carlo Turco; Giulio Sozzi; Matteo Riccò; Benito Chiofalo; Giuseppe Vizzielli
Journal:  Gland Surg       Date:  2020-08

Review 8.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08

Review 9.  Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature.

Authors:  Andrea Rosati; Salvatore Gueli Alletti; Vito Andrea Capozzi; Mariateresa Mirandola; Virginia Vargiu; Camilla Fedele; Stefano Uccella; Carmine Vascone
Journal:  Gland Surg       Date:  2020-08

Review 10.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.